CA2080130A1 - Remedy for obstructive pulmonary diseases - Google Patents
Remedy for obstructive pulmonary diseasesInfo
- Publication number
- CA2080130A1 CA2080130A1 CA 2080130 CA2080130A CA2080130A1 CA 2080130 A1 CA2080130 A1 CA 2080130A1 CA 2080130 CA2080130 CA 2080130 CA 2080130 A CA2080130 A CA 2080130A CA 2080130 A1 CA2080130 A1 CA 2080130A1
- Authority
- CA
- Canada
- Prior art keywords
- obstructive pulmonary
- pulmonary diseases
- compound
- remedy
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
This invention relates to a preventing and treating agent for obstructive pulmonary diseases which comprises 6-(1-imidazolyl-methyl)-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The active ingredient has a function of inhibiting TXA2 synthetase and is thus highly useful in the treatment of obstructive pulmonary diseases (for example, bronchial asthma, diffuse panbronchiolitis, pulmonary emphysema, chronic bronchitis).
This invention relates to a preventing and treating agent for obstructive pulmonary diseases which comprises 6-(1-imidazolyl-methyl)-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The active ingredient has a function of inhibiting TXA2 synthetase and is thus highly useful in the treatment of obstructive pulmonary diseases (for example, bronchial asthma, diffuse panbronchiolitis, pulmonary emphysema, chronic bronchitis).
Description
2~130 SPECIFICATION
REMEDY FOR OBSTRI~CTIVE: PULMONARY DISEASES
TECHNICAL FIELD
This invention relates to a preventing and treating agent for obstructive pulmonary diseases which comprises 6~ imidazolylmethyl)-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid (compound A) or a pharmaceut-ically acceptable salt thereof as an active ingredient.
BACXGROUND ART
The aforesaid compound A inhibits the function of thromboxane A2 (TXA2) synthetase. Namely, it inhibits an enzyme capable of converting a precursor prostaglandin H2 (PGH2) into TXA2 and thus reduces the amount of TxA2 in vivo.
Thus PGH2 is increased and then metabolized into, for example, prostaglandin I2 (PGI2), prostaglandin E2 (PGE2) and prostaglandin F?a (PGF2a). As a result, a decrease in TXA2 and an increase in, for example, PGI2, PGE2 and PGF2a are observed.
TXA2and PGF2a are bronchial constrictor while PGI2 and PGE2 are bronchial dilator.
The bronchoconstriction is one of the causes for obstructive pulmonary diseases which are obstructive disorders in the airway.
Although TXA2 synthetase inhibitors or TXA2 20~ 30 antagonists have been used in clinical tests on bronchial asthma, none of these drugs shows a satisfactory useful-ness.
The compound A suppresses arachidonic acid-induced relaxing responses in guinea pig trachea strips andsuppresses arachidonic acid-induced contractile respGneses in lung ~issue strips.
Acetylcholine-, histamine-, and prostaglandin F2~-induced contractile responses in guinea pig lung andtrachea strips were attenuated significantly by compound A.
As mentioned above, the TXA2synthetase inhibition changes the amounts of prostanoids (for example, decreasing TXA2), and as a result, the resulting suitable prostanoid balance seems to be important for the treatment of obstructive pulmonary diseases. Various TXA2 synthetase inhibitors have each own characteristics and thus differ from each othec in the intensity of action and the degree of changing the prostanoid balance. In addition, the reaction of bronchus varies from species to species, which suggests that the results obtained by using animal sections are not always reproducible in human.
DISCLOSURE OF THE INVENTION
As a remedy for obstructive pulmonary diseases, bronchodilators (for example, sympathomimetic agents, xanthine derivatives and anticholinergic drugs) and 2 ~ 3 ~
antiallergic drugs have been frequently used optionally together with antitussives or expectorants depending on the conditions. In cases on which these drugs can never or hardly achieve any therapeutic effects, corticosteroids, which might induce or deteriorate, for example, infectious diseases, peptic ulcer, psychoneurosis and diabetes, are used.
The present inventors have conducted extensive studies to find a drug which is widely effective for from a mild case to a serious one of obstructive pulmonary diseases and effectively and safely applicable to an advanced case hardly treated even by using an cortico-steroid. As a result, it has now been found that the compound A having a TXA2 synthetase-inhibiting activity exhibits the above-mentioned effects, thus achieving the present invention.
Accordingly, the present invention relates to a drug for preventing or treating obstructive pulmonary diseases which comprises the compound A or a pharmaceuti-cally acceptable salt thereof as an active ingredient.
Pharmaceutically acceptable salts of the compound A include acid addition salts formed with inorganic acids (for example, hydrochloric acid, sulfuric acid, nitric acid, etc.) or organic acids (for example, fumaric acid, tartaric acid, maleic acid, succinic acid, oxalic acid, ~08~3~
etc.), alkali metal salts of carboxyl group ~for example, sodium salt, potassium salt, etc.) and al~aline earth metal salts of carboxyl group (for example, calcium salt, magnesium salt, etc.).
The term "obstructive pulmonary diseasesl' used herein is a general name involving diseases having obstructive disorders of the respiratory tract in common (for example, bronchial asthma, diffuse panbronchiolitis, pulmonary emphysema, chronic bronchitis).
The compound A or a salt thereof can be formulated into various phamaceutical preparations (for example, tablets~ powders, capsules, syrup, inhalation, injection, etc.) by known phamaceutical techniques and is usually administered orally, subcutaneously, intramusculaxly, intrabronchially or intravenously.
The dose level of the compound A or a salt thereof usually ranges from 10 to l,OOO mg/day for adult in oral administral;ion.
The acute toxicity of the compound A hydro-chloride hemihydrate (oral administration to rats, LD50) is 2,438 mgtkg in male or 1,994 mg/kg in female.
BEST NODE FOR C~RRYING OUT THE INVENTION
The present invention is now illustrated in greater detail with reference to the following Examples.
The drug employed in these Examples was prepared 2 ~ 3 ~
by formulating the compound A hydrochloride hemihydrate into oral tablets (hereinafter, referred to merely as ~-tablets A").
Each subject was observed for 2 weeks. Then, the tablets A were given to the subject in a dose of 400 mg/day, in terms of the compound A hydrochloride hemi-hydrate, (two times, after breakfast and before bedtime, per day) for 2 weeks. Then, the differences in conditions and respiratory function of the subject between the observation period and the dosage period were examined.
The same remedies, other than the tablets A, used in the observation period were given in the dosage period too.
EXAMP~E 1 M.K. Female, aged 55 and weighing 55 kg. A case of mixed, chronic and whole year-type bronchial asthma.
Serious conditions requiring the treatment with cortico~
steroids. None of other remedies listed below exerted any sufficient effects. However, the combined use of the tablets A lowered the attack frequency, relieved cou~hing, decreased sputa, changed dry rales to negative, smoothened the daily life and increased da~s of comfortable sleep.
Other remedy: theophylline (800 mg/day), salbutamol hemisulfate (8 mg/day) and prednisolone (10 mg/day).
20~130 D.T. Male, aged 37 and weighing 78 kg. A case of mixed-type bronchial asthma. Serious conditions requir-ing the treatment with corticosteroids. None of other remedies listed below exerted any sufficient effects.
Thus, the tablets A were used together with these remedies.
During the dosage of the tablets A, serious coughing was relieved and the subject could peacefully or almost peace-fully sleep in the night.
Other remedy: theophylline (600 mg/day), pirubuterol hydrochloride (45 mg/day) and predniso-lone (7.5 mg/day).
U.K. Male, aged 61 and weighing 47 kg. A case of mixed, chronic and whole year-type bronchial asthma accompanied by diffuse panbronchiolitis. Serious condîtions requiring the treatment with corticosteroids.
None of other remedies listed below exerted any sufficient effects. However, the combined use of the tablets A
lowered the attack frequency, relieved coughing, improved expectoration, changed dry rales to negative, smoothened the daily life and made sleep in the night peaceful. In addition, the pulmonary function of the subject was remarkably improved.
The patient maintained good physical conditions ~08~13~
after the termination of the dosage.
Other remedy: theophylline (1,500 mg/day) and pred-nisolone (22.5 mg/day).
Table 1 shows the data relating to the function of the tablets A of inhibiting the synthesis of TXA2 and its effects on other prostanoids.
Table 2 shows the data relating to pulmonary functions determined in Examples 1 and 3.
'~ O ~ ~ ~
O ~ V ~
.
Q
~ a ~ v U~ b :~ O
~ ~ "~ O ~ O
", a a 4 b¦~ ~e -~3 1 u o E ~ n I R. ~ O v a~ X .~ s- ~ ~ ~, O ~ , O O ~ ~t Qn ~ :~ ~ ~ ~ V V :~
~ ' t-t ~ a) ~
~ X ~ ~
H
O Q
.~ ~ ~
)~ at t K
~ X
E~
REMEDY FOR OBSTRI~CTIVE: PULMONARY DISEASES
TECHNICAL FIELD
This invention relates to a preventing and treating agent for obstructive pulmonary diseases which comprises 6~ imidazolylmethyl)-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid (compound A) or a pharmaceut-ically acceptable salt thereof as an active ingredient.
BACXGROUND ART
The aforesaid compound A inhibits the function of thromboxane A2 (TXA2) synthetase. Namely, it inhibits an enzyme capable of converting a precursor prostaglandin H2 (PGH2) into TXA2 and thus reduces the amount of TxA2 in vivo.
Thus PGH2 is increased and then metabolized into, for example, prostaglandin I2 (PGI2), prostaglandin E2 (PGE2) and prostaglandin F?a (PGF2a). As a result, a decrease in TXA2 and an increase in, for example, PGI2, PGE2 and PGF2a are observed.
TXA2and PGF2a are bronchial constrictor while PGI2 and PGE2 are bronchial dilator.
The bronchoconstriction is one of the causes for obstructive pulmonary diseases which are obstructive disorders in the airway.
Although TXA2 synthetase inhibitors or TXA2 20~ 30 antagonists have been used in clinical tests on bronchial asthma, none of these drugs shows a satisfactory useful-ness.
The compound A suppresses arachidonic acid-induced relaxing responses in guinea pig trachea strips andsuppresses arachidonic acid-induced contractile respGneses in lung ~issue strips.
Acetylcholine-, histamine-, and prostaglandin F2~-induced contractile responses in guinea pig lung andtrachea strips were attenuated significantly by compound A.
As mentioned above, the TXA2synthetase inhibition changes the amounts of prostanoids (for example, decreasing TXA2), and as a result, the resulting suitable prostanoid balance seems to be important for the treatment of obstructive pulmonary diseases. Various TXA2 synthetase inhibitors have each own characteristics and thus differ from each othec in the intensity of action and the degree of changing the prostanoid balance. In addition, the reaction of bronchus varies from species to species, which suggests that the results obtained by using animal sections are not always reproducible in human.
DISCLOSURE OF THE INVENTION
As a remedy for obstructive pulmonary diseases, bronchodilators (for example, sympathomimetic agents, xanthine derivatives and anticholinergic drugs) and 2 ~ 3 ~
antiallergic drugs have been frequently used optionally together with antitussives or expectorants depending on the conditions. In cases on which these drugs can never or hardly achieve any therapeutic effects, corticosteroids, which might induce or deteriorate, for example, infectious diseases, peptic ulcer, psychoneurosis and diabetes, are used.
The present inventors have conducted extensive studies to find a drug which is widely effective for from a mild case to a serious one of obstructive pulmonary diseases and effectively and safely applicable to an advanced case hardly treated even by using an cortico-steroid. As a result, it has now been found that the compound A having a TXA2 synthetase-inhibiting activity exhibits the above-mentioned effects, thus achieving the present invention.
Accordingly, the present invention relates to a drug for preventing or treating obstructive pulmonary diseases which comprises the compound A or a pharmaceuti-cally acceptable salt thereof as an active ingredient.
Pharmaceutically acceptable salts of the compound A include acid addition salts formed with inorganic acids (for example, hydrochloric acid, sulfuric acid, nitric acid, etc.) or organic acids (for example, fumaric acid, tartaric acid, maleic acid, succinic acid, oxalic acid, ~08~3~
etc.), alkali metal salts of carboxyl group ~for example, sodium salt, potassium salt, etc.) and al~aline earth metal salts of carboxyl group (for example, calcium salt, magnesium salt, etc.).
The term "obstructive pulmonary diseasesl' used herein is a general name involving diseases having obstructive disorders of the respiratory tract in common (for example, bronchial asthma, diffuse panbronchiolitis, pulmonary emphysema, chronic bronchitis).
The compound A or a salt thereof can be formulated into various phamaceutical preparations (for example, tablets~ powders, capsules, syrup, inhalation, injection, etc.) by known phamaceutical techniques and is usually administered orally, subcutaneously, intramusculaxly, intrabronchially or intravenously.
The dose level of the compound A or a salt thereof usually ranges from 10 to l,OOO mg/day for adult in oral administral;ion.
The acute toxicity of the compound A hydro-chloride hemihydrate (oral administration to rats, LD50) is 2,438 mgtkg in male or 1,994 mg/kg in female.
BEST NODE FOR C~RRYING OUT THE INVENTION
The present invention is now illustrated in greater detail with reference to the following Examples.
The drug employed in these Examples was prepared 2 ~ 3 ~
by formulating the compound A hydrochloride hemihydrate into oral tablets (hereinafter, referred to merely as ~-tablets A").
Each subject was observed for 2 weeks. Then, the tablets A were given to the subject in a dose of 400 mg/day, in terms of the compound A hydrochloride hemi-hydrate, (two times, after breakfast and before bedtime, per day) for 2 weeks. Then, the differences in conditions and respiratory function of the subject between the observation period and the dosage period were examined.
The same remedies, other than the tablets A, used in the observation period were given in the dosage period too.
EXAMP~E 1 M.K. Female, aged 55 and weighing 55 kg. A case of mixed, chronic and whole year-type bronchial asthma.
Serious conditions requiring the treatment with cortico~
steroids. None of other remedies listed below exerted any sufficient effects. However, the combined use of the tablets A lowered the attack frequency, relieved cou~hing, decreased sputa, changed dry rales to negative, smoothened the daily life and increased da~s of comfortable sleep.
Other remedy: theophylline (800 mg/day), salbutamol hemisulfate (8 mg/day) and prednisolone (10 mg/day).
20~130 D.T. Male, aged 37 and weighing 78 kg. A case of mixed-type bronchial asthma. Serious conditions requir-ing the treatment with corticosteroids. None of other remedies listed below exerted any sufficient effects.
Thus, the tablets A were used together with these remedies.
During the dosage of the tablets A, serious coughing was relieved and the subject could peacefully or almost peace-fully sleep in the night.
Other remedy: theophylline (600 mg/day), pirubuterol hydrochloride (45 mg/day) and predniso-lone (7.5 mg/day).
U.K. Male, aged 61 and weighing 47 kg. A case of mixed, chronic and whole year-type bronchial asthma accompanied by diffuse panbronchiolitis. Serious condîtions requiring the treatment with corticosteroids.
None of other remedies listed below exerted any sufficient effects. However, the combined use of the tablets A
lowered the attack frequency, relieved coughing, improved expectoration, changed dry rales to negative, smoothened the daily life and made sleep in the night peaceful. In addition, the pulmonary function of the subject was remarkably improved.
The patient maintained good physical conditions ~08~13~
after the termination of the dosage.
Other remedy: theophylline (1,500 mg/day) and pred-nisolone (22.5 mg/day).
Table 1 shows the data relating to the function of the tablets A of inhibiting the synthesis of TXA2 and its effects on other prostanoids.
Table 2 shows the data relating to pulmonary functions determined in Examples 1 and 3.
'~ O ~ ~ ~
O ~ V ~
.
Q
~ a ~ v U~ b :~ O
~ ~ "~ O ~ O
", a a 4 b¦~ ~e -~3 1 u o E ~ n I R. ~ O v a~ X .~ s- ~ ~ ~, O ~ , O O ~ ~t Qn ~ :~ ~ ~ ~ V V :~
~ ' t-t ~ a) ~
~ X ~ ~
H
O Q
.~ ~ ~
)~ at t K
~ X
E~
~, ~ O O
X ~ o~ ~ ~
O~ R~ ~ ~ S
5) a. 1, o . ~ 0 ,. ~
3 > ~
~ o o ~ ~ ~ ~
~ ~ , Zl INDUSTRIA:L APPLICABILITY
According to the present invention, the oral administration of 6~ imidazolylmethyl)-5,6,7,8-tetra-hydronaphthalene-2-carboxylic acid (compound A) to patients suffering from bronchial asthma and diffuse panbron-chiolitis, as typical examples of obstructive pulmonary diseases, resulted in the improvement in subjective symptoms and a decrease in attack frequency.
The cases shown in Examples are hardly curable obstructive pulmonary diseases, in particular, bronchial asthma on which even corticosteroids could not exert any sufficient therapeutic effects. Thus, it may be concluded that the compound A is highly useful. In particular, the administration of compound A for 2 weeks exerted remarkable therapeutic effects on diffuse panbronchiolitis, which is frequently followed by unfavorable prognosis, and the patient maintai.ned good physical conditions after the termination of the dosage. Therefore, the compound A is available as a quick and eradicative drug for this disease.
X ~ o~ ~ ~
O~ R~ ~ ~ S
5) a. 1, o . ~ 0 ,. ~
3 > ~
~ o o ~ ~ ~ ~
~ ~ , Zl INDUSTRIA:L APPLICABILITY
According to the present invention, the oral administration of 6~ imidazolylmethyl)-5,6,7,8-tetra-hydronaphthalene-2-carboxylic acid (compound A) to patients suffering from bronchial asthma and diffuse panbron-chiolitis, as typical examples of obstructive pulmonary diseases, resulted in the improvement in subjective symptoms and a decrease in attack frequency.
The cases shown in Examples are hardly curable obstructive pulmonary diseases, in particular, bronchial asthma on which even corticosteroids could not exert any sufficient therapeutic effects. Thus, it may be concluded that the compound A is highly useful. In particular, the administration of compound A for 2 weeks exerted remarkable therapeutic effects on diffuse panbronchiolitis, which is frequently followed by unfavorable prognosis, and the patient maintai.ned good physical conditions after the termination of the dosage. Therefore, the compound A is available as a quick and eradicative drug for this disease.
Claims
1. A preventing and treating agent for obstruc-tive pulmonary diseases which comprises 6-(1-imidazolyl-methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9358490 | 1990-04-09 | ||
| JP2-93584 | 1990-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2080130A1 true CA2080130A1 (en) | 1991-10-10 |
Family
ID=14086333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2080130 Abandoned CA2080130A1 (en) | 1990-04-09 | 1991-04-09 | Remedy for obstructive pulmonary diseases |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0526638A4 (en) |
| CA (1) | CA2080130A1 (en) |
| WO (1) | WO1991015207A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6479116A (en) * | 1987-06-10 | 1989-03-24 | Daiichi Seiyaku Co | Remedy for renal disease |
| IL86846A (en) * | 1987-07-01 | 1992-03-29 | Daiichi Seiyaku Co | Pharmaceutical compositions for preventing and treating heart failure containing indane or naphthalene carboxylic acids |
| CA1332357C (en) * | 1988-06-17 | 1994-10-11 | Daiichi Seiyaku Co., Ltd. | Treating agent for peripheral circulatory disturbances |
-
1991
- 1991-04-09 EP EP19910906688 patent/EP0526638A4/en not_active Withdrawn
- 1991-04-09 WO PCT/JP1991/000470 patent/WO1991015207A1/en not_active Application Discontinuation
- 1991-04-09 CA CA 2080130 patent/CA2080130A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991015207A1 (en) | 1991-10-17 |
| EP0526638A1 (en) | 1993-02-10 |
| EP0526638A4 (en) | 1993-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9446054B2 (en) | Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids | |
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| EP1446119B1 (en) | Compositions comprising ipatropium and xylometazoline for treatment of the common cold | |
| SK82296A3 (en) | Use of mometasone fluroate for treating airway passage and lung diseases | |
| JPH0717867A (en) | Chemical for respiratory organ system disease medical treatment | |
| JP3348858B2 (en) | Antitussive composition comprising antitussive and benzydamine | |
| EP0171227B1 (en) | Use of propiophenone compound | |
| EA009935B1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| EP0640338A1 (en) | Sodium cromoglycate for the treatment of upper respiratory tract infections | |
| KR101697773B1 (en) | Modified release composition comprising doxofylline | |
| CA2080130A1 (en) | Remedy for obstructive pulmonary diseases | |
| AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
| AU2002236141B2 (en) | Method of treatment | |
| JP2002531495A (en) | Beaupropion for treating viral diseases | |
| EA009990B1 (en) | Synergistic combination comprising roflumilast and (r,r) -formoterol | |
| JPH072697A (en) | Local medicinal composition to respiratory allergy | |
| McDonald et al. | Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction | |
| JP3254712B2 (en) | Pharmaceutical composition | |
| JPWO2004039408A1 (en) | Pharmaceutical composition | |
| JP2003506402A (en) | Use of a 5-HT3 receptor antagonist for the treatment of airway inflammation | |
| Van Keimpema et al. | Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients | |
| JP2001089375A (en) | Common cold composition | |
| AU2002329578B2 (en) | Compositions for treatment of common cold | |
| Weinberger et al. | Management of asthma: 2. Antiasthmatic drugs | |
| BG98678A (en) | Antiasthma medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |